H80-MC-GWBQ Efficacy of Exenatide in Adolescent Patients with Type 2 Diabetes
ID Number 08-0899Principal Investigator(s)
Department(s) or Division(s)
The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) from baseline to endpoint, with exenatide is superior to that of placebo after 28 weeks of treatment in adolescent patientswith type 2 diabetes who are naïve to antidiabetic agents (with or without diet and exercise), or who are being treated with Met, SU, or a combination of Met and SU, (withor without diet and exercise).
Robert Rapaport, MD
Recruiting Patients: No